clinical trials

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

enGene's president and chief executive, Ron Cooper

Trial sets up filing for enGene bladder cancer gene therapy

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

News

AHA: MSD's oral PCSK9 matches injectables

MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.

News

Roche chief medical officer Levi Garraway

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.

News

AHA: AZ's baxdrostat impresses in resistant hypertension

AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.

News

Intellia shares fall after hospitalised CRISPR patient dies

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.

Alkermes breaks new ground in narcolepsy with orexin drug

Trial sets up filing for enGene bladder cancer gene therapy

AHA: MSD's oral PCSK9 matches injectables

Roche's oral MS hope fenebrutinib hits the mark in phase 3

AHA: AZ's baxdrostat impresses in resistant hypertension

Intellia shares fall after hospitalised CRISPR patient dies

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks